KR20220152292A - 코로나바이러스과 감염을 치료 또는 예방하기 위한 화합물, 및 코로나바이러스과 감염의 발생을 평가하기 위한 방법 및 용도 - Google Patents

코로나바이러스과 감염을 치료 또는 예방하기 위한 화합물, 및 코로나바이러스과 감염의 발생을 평가하기 위한 방법 및 용도 Download PDF

Info

Publication number
KR20220152292A
KR20220152292A KR1020227035066A KR20227035066A KR20220152292A KR 20220152292 A KR20220152292 A KR 20220152292A KR 1020227035066 A KR1020227035066 A KR 1020227035066A KR 20227035066 A KR20227035066 A KR 20227035066A KR 20220152292 A KR20220152292 A KR 20220152292A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
infection
compound
coronavirus
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227035066A
Other languages
English (en)
Korean (ko)
Inventor
자말 타지
하르트무트 에를리히
필립 풀레티
줄리앙 산토
디디어 셰레
Original Assignee
아비박스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20305299.8A external-priority patent/EP3881844A1/en
Priority claimed from EP20305327.7A external-priority patent/EP3884946A1/en
Application filed by 아비박스 filed Critical 아비박스
Publication of KR20220152292A publication Critical patent/KR20220152292A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020227035066A 2020-03-20 2021-03-19 코로나바이러스과 감염을 치료 또는 예방하기 위한 화합물, 및 코로나바이러스과 감염의 발생을 평가하기 위한 방법 및 용도 Ceased KR20220152292A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20305299.8A EP3881844A1 (en) 2020-03-20 2020-03-20 Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
EP20305299.8 2020-03-20
EP20305327.7A EP3884946A1 (en) 2020-03-25 2020-03-25 Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
EP20305327.7 2020-03-25
EP20305482 2020-05-12
EP20305482.0 2020-05-12
EP20306483.7 2020-12-03
EP20306483 2020-12-03
PCT/EP2021/057123 WO2021186053A1 (en) 2020-03-20 2021-03-19 Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection

Publications (1)

Publication Number Publication Date
KR20220152292A true KR20220152292A (ko) 2022-11-15

Family

ID=74884979

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227035066A Ceased KR20220152292A (ko) 2020-03-20 2021-03-19 코로나바이러스과 감염을 치료 또는 예방하기 위한 화합물, 및 코로나바이러스과 감염의 발생을 평가하기 위한 방법 및 용도

Country Status (11)

Country Link
US (1) US20230142547A1 (https=)
EP (1) EP4121053A1 (https=)
JP (1) JP2023521564A (https=)
KR (1) KR20220152292A (https=)
CN (1) CN115605205A (https=)
AU (1) AU2021238792A1 (https=)
BR (1) BR112022018793A2 (https=)
CA (1) CA3172179A1 (https=)
IL (1) IL296522A (https=)
MX (1) MX2022011596A (https=)
WO (1) WO2021186053A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions
CN118373771A (zh) * 2023-01-20 2024-07-23 江苏柯菲平医药股份有限公司 一种喹啉衍生化合物或其可药用的盐及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070225363A1 (en) 2003-11-21 2007-09-27 The University Of Newcastle Research Associates Ltd. Methods and Agents for Inhibiting Dynamin-Dependent Endocytosis
SI2440547T1 (sl) 2009-06-12 2023-05-31 Abivax Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
EP2862928A1 (en) 2013-10-18 2015-04-22 Université de Strasbourg Dynamin 2 inhibitor for the treatment of centronuclear myopathies
EP3058940A1 (en) * 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection
EP3059236A1 (en) * 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
EP3594206A1 (en) 2018-07-09 2020-01-15 Abivax Phenyl-n-quinoline derivatives for treating a rna virus infection
EP3858815A1 (en) * 2020-01-31 2021-08-04 Abivax Co-crystals and salts of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
CA3164700A1 (en) * 2020-01-31 2021-08-05 Abivax Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
KR20210151949A (ko) * 2020-04-05 2021-12-14 화이자 인코포레이티드 Covid-19의 치료를 위한 화합물 및 방법

Also Published As

Publication number Publication date
JP2023521564A (ja) 2023-05-25
EP4121053A1 (en) 2023-01-25
AU2021238792A1 (en) 2022-10-13
BR112022018793A2 (pt) 2022-11-29
WO2021186053A1 (en) 2021-09-23
CA3172179A1 (en) 2021-09-23
MX2022011596A (es) 2022-10-18
CN115605205A (zh) 2023-01-13
US20230142547A1 (en) 2023-05-11
IL296522A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
KR102254315B1 (ko) 글루타르이미드 유도체, 이의 용도, 이를 기반으로 한 약학 조성물 및 글루타르이미드 유도체를 생산하는 방법
AU2022283635B2 (en) Detection of viral infection
EP2825173B1 (en) Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
JP2010504332A (ja) アルツハイマー病の診断方法及び遺伝子マーカー
KR20220152292A (ko) 코로나바이러스과 감염을 치료 또는 예방하기 위한 화합물, 및 코로나바이러스과 감염의 발생을 평가하기 위한 방법 및 용도
CA2971369A1 (en) Compound for treatment of myotonic dystrophy type 1
JP7805038B2 (ja) 筋肉量及び酸化的代謝を増加させるための組成物及び方法
CN111886026A (zh) 用于治疗或预防高细胞因子血症和重度流感的方法和化合物
CN107164528B (zh) 一种与肝癌发生发展相关的非编码基因的应用
CN108165632B (zh) Linc01426在肝细胞癌诊断和治疗中的应用
EP3884946A1 (en) Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
HK40077570A (en) Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
CN114525342B (zh) Linc02806在肝细胞癌诊断和治疗中的应用
WO2023170187A1 (en) INHIBITION OF INTRACELLULAR PATHOGEN UPTAKE BY INHIBITORS OF THE IKK-α/NIK COMPLEX
WO2005112924A2 (en) Methods of treating cancer by inhibiting histone gene expression
EP3881844A1 (en) Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
JP6452954B2 (ja) 癌転移抑制剤
US12310947B2 (en) Methods and compositions for unsilencing imprinted genes
US20240150759A1 (en) Splicing Modulators for the Treatment of Timothy Syndrome
EA046703B1 (ru) Ингибиторы киназы р38 снижают экспрессию dux4 и последующих генов для лечения fshd
US20150104440A1 (en) MiRNA-31 AS A DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC AGENT IN CANCER
JP2024541938A (ja) Ａｌｓ／ｆｔｄを治療するための小分子分解方法
KR20240017323A (ko) Gcc2 발현 억제제를 유효성분으로 포함하는 폐암 예방또는 치료용 약학적 조성물
HK1218766B (zh) 作为生物标记物的mirna-124
HK40006861A (en) Calcium channel blockers for the treatment of ribosomal disorders and ribosomapathies

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20221007

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221007

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250225

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250429

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D